Cerity Partners
CTKB icon

Cerity Partners’s Cytek Biosciences CTKB Stock Holding History

Cerity Partners’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Buy
58,123
+8,595
+17% +$40.6K ﹤0.01% 2727
2025
Q4 		$250K Sell
49,528
-2,461
-5% -$11.4K ﹤0.01% 2513
2025
Q3 		$180K Buy
51,989
+627
+1% +$2.35K ﹤0.01% 2529
2025
Q2 		$175K Buy
+51,362
New +$171K ﹤0.01% 2389
2024
Q3 		– Sell
-11,815
Closed -$65.9K – 2552
2024
Q2 		$65.9K Buy
+11,815
New +$71K ﹤0.01% 2149

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cerity Partners's CTKB Position: Q1 2026 in Review

Cerity Partners increased its Cytek Biosciences (CTKB) stake by 17% in Q1 2026, buying an estimated $40.6K and bringing the position to 58,123 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #2727.

Cerity Partners first reported a position in CTKB in Q2 2024 and has held it in 5 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Cerity Partners held 58,123 shares of Cytek Biosciences worth $254K as of Q1 2026.
  • Cerity Partners bought 8,595 Cytek Biosciences shares in Q1 2026, an estimated $40.6K.
  • Cytek Biosciences made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2727 holding.
  • Cerity Partners first reported a position in Cytek Biosciences in Q2 2024 and has held it in 5 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.